Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samyr adjunctive therapy versus placebo in major depressive disorder
2024-513019-29-00Phase 3Authorised
- Sponsor
- Mylan
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Samyr adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Change from baseline in HDRS-17 score at 6 weeks. Planned start Mar 2024; status: authorised.
02
Drugs
S-adenosylmethionine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-513019-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513019-29-00.